Tpharm.info


Zanidip interactions





Zanidip 10mg tablets - high blood pressure - eMC Medicines Guides

01/01/2015
08:27 | Author: Kayla Henderson

Cholesterol medication side effects liver
Zanidip 10mg tablets - high blood pressure - eMC Medicines Guides

Information about Zanidip used in the treatment of high blood pressure. for you and side effects and interactions with other medicines.

If you are taking Zanidip and one of the above medicines or types of medicines, make sure your prescriber knows about it.

The following medicines may interact with Zanidip:

Alcohol can interact with certain medicines.

You should discuss your personal circumstances with your doctor if you are pregnant or want to become pregnant. This is so that together you can make a decision about what treatment you may need during your pregnancy.

Select your preparation (type) of Zanidip.

Suddenly stopping your medicine may cause your original condition to return.

Comments (1)Read more



Lercanidipine (Zanidip) Side Effects, Dosage, Interaction Information

01/01/2015
06:06 | Author: Emma Coleman

Cholesterol medication side effects liver
Lercanidipine (Zanidip) Side Effects, Dosage, Interaction Information

What is Lercanidipine (Zanidip)? Lercanidipine belongs to category of no notable drug interactions drugs. Lercanidipine is a type of calcium.

Mail (will not be published) (required) Website Cancel Reply.

Cure Talk is not a traditional health care blog, we are not a re-hash of mainstream health. We communicate the future of medicine. We bring to life stories about new medicine, clinical trials and cutting edge treatments. Our blog speaks volumes!

No notable drug interactions.

It is a new longacting dihydropyridine Calcium Channel Blocker (CCB) which selectively inhibits the influx of extra cellular calcium through voltagegated calcium channels. Lercanidipine is a calcium channel blocker of the dihydropyridine class. Lercanidipine works by slowing the movement of calcium through the muscle cells that are found in the walls of blood vessels. It does this by blocking calcium channels in these muscle cells. Calcium is needed by muscle cells so that they can contract. Lercanidipine reduces the amount of calcium available to muscle cells and so makes them relax. Lercanidipine can also have a widening effect on the small arteries in the heart, which improves the supply of blood, and therefore the oxygen to the heart. This reduces the effort the heart has to make to pump blood around the body. This drug is commonly sold as Brand Name Zanidip.

In hepatic and renal impairment, left ventricular dysfunction, sick sinus syndrome (if pacemaker not fitted), avoid grape fruit juice (may affect metabolism). Name (required).

Initially 10mg once daily, increased, if necessary, after at least 2 weeks to 20mg daily.

Lercanidipine belongs to category of no notable drug interactions drugs. Lercanidipine is a type of calcium channel blockers.

Comments (0)

Zanidip Dosage Drug Information Thailand

01/01/2015
04:59 | Author: Brandon Powell

Cholesterol medication side effects liver
Zanidip Dosage Drug Information Thailand

Digoxin (closely monitor patient). Cimetidine (>800 mg/day). Amiodarone, midazolam, diazepam, metoprolol, propranolol.

Comments (0)

Differences in lercanidipine systemic exposure when administered

01/01/2015
02:32 | Author: Emma Coleman

Cholesterol medication side effects liver
Differences in lercanidipine systemic exposure when administered

to compare the systemic exposure of lercanidipine (Zanidip) after oral compared to estimate the drug–food interaction and the similarity of.

The results of three pilot bioequivalence studies performed to develop a lercanidipine generic product, where Zanidip was administered consistently as reference product in the fasted state or 15 min before a standard breakfast, were compared to estimate the drug–food interaction and the similarity of the methods of administration defined in the SPC.

As intake with a carbohydrate-rich meal is not recommended in the SPC of Zanidip because a twofold difference was considered to be clinically relevant, the intake of lercanidipine only 15 min before food intake does not seem to be consistent with this recommendation. The Marketing Authorisation Holder should clarify the dosing instructions in relation to meals and identify a sufficient time-lapse to ensure an exposure similar to that obtained in phase III clinical efficacy studies.

The ingestion of a standard (non-high-fat, non-high-calorie) meal 15 min after drug intake increased the area under the concentration–time curve (AUC(0-t)) of S-lercanidipine by 1.78-fold [90% confidence interval (CI) 1.48–2.15, P<0.0001] and the maximum concentration (Cmax) of Slercanidipine by 1.82-fold (90% CI 1.46–2.28, P<0.0001). These values are close to the twofold increase that has been described when Zanidip was taken immediay after a carbohydrate-rich meal. Higher levels would be expected with a high-fat, high-calorie meal.

Warning: The NCBI web site requires JavaScript to function. more.

Generate a file for use with external citation management software.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

The aim of this study was to compare the systemic exposure of lercanidipine (Zanidip) after oral administration in the fasted state and 15 min before food intake (meals) to investigate if the recommendations in the Summary of Product Characteristics (SPC) with respect to the intake of meals are adequate.

Comments (0)